Thrombin Regulation in Children Differs from Adults in the Absence and Presence of Heparin

Summary

The physiologic mechanisms that protect children from thromboembolic complications are not known. We investigated the regulation of thrombin in children because of its central importance to thrombosis. The capacity to generate thrombin in vitro (chromogenic assay) was decreased by 26% in plasmas from children (1-16 yrs; n = 102) compared to adults ([20-45 yrs; n = 20; p <0.001]). The addition of purified prothrombin to plasmas from children increased thrombin generation to adult values. The capacity of plasmas to inhibit 125^I-α-thrombin was increased by 21% in children compared to adults (p = 0.020), with significantly more thrombin complexed to a2-macroglobulin (α²M) in children.

When DVT occur in children, adult guidelines for heparin therapy are used. At low heparin concentrations (0.1 and 0.2 U/ml), thrombin generation was decreased by 30% in children compared to adults (p <0.001). At high heparin levels (0.4 U/ml), thrombin generation was negligible in all plasmas. ATIII inhibited over 95% of thrombin in all plasmas in the presence of heparin.

In summary, thrombin regulation differs in children from adults and may protect children from thromboembolic complications. When DVT do occur, heparin requirements may differ in children compared to adults.

• References

• Andrew M, Schmidt B, Mitchell L, Paes B, Ofosu F. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990; 63: 27-30
• 2 Xi M, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 1989; 62 (02) 788-791
• 3 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80 (08) 1998-2005
• 4 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72: 1651-1657
• 5 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987; 70 (01) 165-172
• 6 Ganrot PO, Schersten B. Serum β₂-macroglobulin concentration and its variation with age and sex. Clin Chim Acta 1967; 15: 113-120
• 7 Mitchell L, Piovella F, Ofosu F, Andrew M. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III deficient children. Blood 1991; 78 (09) 2299-2304
• 8 David M, Andrew M. Venous thromboembolism complications in children: A Critical Review of the Literature. J Pediatr 1993; 123 (03) 337-346
• 9 Andrew M, Marzinotto V, Brooker L, Adams M, Ginsberg J, Freedom R, Williams W. Oral anticoagulant therapy in pediatric patients: A prospective study. Thromb Haemost 1994; 71 (03) 265-269
• 10 Mancini G, Carbonara O, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. J Immunochem 1965; 2: 235-254
• 11 Laurell CB. Antigen-antibody crossed electrophoresis. Anal Biochem 1965; 10: 358-361
• 12 Scully MF, Kakkar VV. Methods for semi micro or automated determination of thrombin, antithrombin, and heparin cofactor using the substrate nitroanalide, H-D-Phe-Pip-Ang-p <.2HCI. Clin Chim Acta 1977; 79: 595-600
• 13 Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Fenton JW, Blajchman MA. Unfractionated heparin inhibits thrombin-catalaysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989; 257: 143-150
• 14 Schmidt B, Ofosu FA, Mitchell L, Brooker LA, Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25: 405-408
• 15 Morrison M, Bayse GS. Catalysis of iodination by lactoperoxidase. Biochem 1970; 9: 2995-3000
• 16 Tollefsen DM. HCII. J Biol Chem 1982; 257: 2162
• 17 Fernandez FA, Buchanan MR, Hirsh J, Fenton JW, Ofosu FA. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits. Thromb Haemost 1987; 47: 286-293
• 18 Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In: Hemostasis and Thrombosis - Principles and Clinical Practice Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds). Philadelphia:: JB Lippincott Company; 1987: 3-8
• 19 Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254 (20) 10421-10425
• 20 Jesty J. The kinetics of inhibition of thrombin by antithrombin in the presence of components of the hemostatic system. Blood 1985; 66: 1189
• 21 Fischer AM. Respective roles of ATIII and ;2₂M in thrombin inactivation. Thromb Haemost 1981; 45: 51-54
• 22 Schmidt B, Mitchell L, Ofosu F, Andrew M. Alpha-2-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma. Thromb Haemost 1989; 62: 1074-1077
• 23 Shah JK, Mitchell LG, Paes B, Ofosu FA, Schmidt B, Andrew M. Thrombin inhibition is impaired in plasma of sick neonates. Pediatr Res 1992; 31: 391-395
• 24 Yuen PMP, Yin JA, Lao TTH. Fibrino-peptide A levels in maternal and newborn plasma. Eur J Obstet Gynecol 1989; 30: 239
• 25 Suarez CR, Gonzalez J, Menendez C, Fareed J, Fresco R, Walenga J. Neonatal and maternal platelets: Activation at time of birth. Am J Hematol 1988; 29: 18-21
• 26 Suarez CR, Menendez CE, Walenga JM, Fareed J. Neonatal and maternal hemostasis. Value of molecular markers in the assessment of hemostatic status. Semin Thromb Haemost 1984; 10: 280-284
• 27 Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest 1987; 80: 1527-1534
• 28 Hirsh J, Hull RD. Venous Thromboembolism. In: Natural History, Diagnosis and Management Boca Raton, Florida: CRC Press; 1987: 117
• 29 Hirsh J. Heparin. N Engl J Med 1991; 324 (22) 1565-1574